BIOSTAR PHARM-B: May 2026 Filing Shows Stable Capital Base and Sufficient Public Float

Bulletin Express
06/02

Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) reported no changes in its share capital structure for the month ended 31 May 2026, according to its Monthly Return filed with Hong Kong Exchanges and Clearing Limited on 02 June 2026.

Registered and Issued Share Capital • Registered share capital remained at RMB 364.59 million, divided into 364.59 million H-shares with a par value of RMB 1 each. • The issued share count was unchanged at 364.59 million shares, and the company held no treasury shares at month-end.

Public Float Compliance The company confirmed compliance with the Main Board’s minimum public float requirement of 25% of issued H-shares as of 31 May 2026.

Corporate Actions • No share issuances, cancellations, repurchases, option grants, warrant exercises, convertible securities, or other equity-related transactions were recorded during the month.

Recent Context Biostar completed full share circulation on 30 March 2026 by converting 147.87 million unlisted shares into H-shares, a move that established the current share count and capital structure.

Administrative Details The filing was submitted by Company Secretary Chan Yik Pun, with no additional confirmations or amendments required under the Listing Rules.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10